A lysine-addition trick improved synthesis of the difficult Alzheimer's peptide Aβ42 and revealed that the rarer Aβ46 forms amyloid plaques even faster.
Aβ46 aggregates fastestDespite being rare in the brain, the newly synthesized Aβ46 formed amyloid fibrils significantly faster than the better-known Aβ42 or Aβ40
What the researchers found
A new method for synthesizing hydrophobic amyloid-beta peptides was developed by temporarily adding lysine residues to the C-terminus during synthesis, then removing them enzymatically with carboxypeptidase B. This produced Aβ42 of quality rivaling recombinant expression — a significant improvement over standard synthesis.
The method also enabled synthesis of Aβ46, which was found to form amyloid fibrils significantly faster than Aβ42 or Aβ40. Despite being present in low amounts in the human brain, Aβ46's enhanced amyloidogenicity suggests it could play a disproportionate role in initiating Alzheimer's plaque formation.
Why it matters
Alzheimer's research depends on having pure, well-characterized amyloid-beta peptides. The more toxic Aβ42 has been notoriously difficult to synthesize chemically. This method solves a practical bottleneck in Alzheimer's research and also reveals that Aβ46 — a less-studied variant — may be an important early driver of plaque formation.
The numbers in context
Aβ42 and Aβ46 synthesized · Quality rivals recombinant expression · Aβ46 aggregates faster than Aβ42 or Aβ40 · CPB-mediated Lys removal · Applicable to any sequence not ending in Arg/Lys
How the study worked
Chemical synthesis study using Fmoc solid-phase peptide synthesis with C-terminal lysine additions. Post-purification enzymatic removal of lysines using immobilized carboxypeptidase B. Product quality verified by HPLC and mass spectrometry. Amyloid formation kinetics of the synthesized peptides (Aβ40, Aβ42, Aβ46) were characterized.
Who was studied
Not applicable (chemical synthesis and biophysical characterization study)
What this study cannot tell us
This is a chemistry methods paper focused on synthesis quality. The biological significance of Aβ46 is speculative based on in vitro aggregation kinetics only. The method cannot be used for peptides naturally ending in arginine or lysine. No cell-based or in vivo validation of the synthesized peptides' biological activity was performed.
How to read the evidence
This is a chemical methodology study with important biophysical observations. While technically rigorous, the biological implications of Aβ46's rapid aggregation are speculative and require in vivo validation.
When this study was published
Published in 2014, this method has been available for over a decade. The observation about Aβ46 aggregation kinetics remains relevant to ongoing Alzheimer's research into amyloid seeding and initiation.
The bigger picture
High-quality synthetic amyloid peptides are essential tools for Alzheimer's drug discovery — testing potential treatments requires pure, well-characterized peptides. This method removes a significant barrier. The finding that Aβ46 aggregates fastest is also important: if this rare variant seeds plaque formation, it could represent an overlooked therapeutic target.
Questions still open
- Does Aβ46 seed the aggregation of more abundant Aβ40 and Aβ42 in the brain?
- Could targeting Aβ46 production or clearance be a new Alzheimer's prevention strategy?
- Is this lysine-addition synthesis method applicable to other difficult-to-make therapeutic peptides?
Common questions
Why is Aβ42 so hard to make in the lab?
Could Aβ46 be important in Alzheimer's disease?
Read the original research
Improved chemical synthesis of hydrophobic Aβ peptides using addition of C-terminal lysines later removed by carboxypeptidase B.
Biopolymers, 102(2), 206-21
Citation
Chemuru, Saketh; Kodali, Ravindra; Wetzel, Ronald. (2014). Improved chemical synthesis of hydrophobic Aβ peptides using addition of C-terminal lysines later removed by carboxypeptidase B.. Biopolymers, 102(2), 206-21. https://doi.org/10.1002/bip.22470